98 related articles for article (PubMed ID: 9511716)
1. Peds nurses prepare for RSV season.
Abel J
Nurs Spectr (Wash D C); 1998 Jan; 8(2):17. PubMed ID: 9511716
[No Abstract] [Full Text] [Related]
2. Nurse role in RSV management.
Whelan B
Early Hum Dev; 2012 May; 88 Suppl 2():S29-30. PubMed ID: 22633508
[No Abstract] [Full Text] [Related]
3. An infection out of season: respiratory syncytial virus.
Purssell E
Paediatr Nurs; 1998 Oct; 10(8):27-8. PubMed ID: 10095672
[No Abstract] [Full Text] [Related]
4. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
5. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
7. A common ailment.
Purssell E; Gould D
Nurs Times; 1997 Jan 15-21; 93(3):53-6. PubMed ID: 9043336
[No Abstract] [Full Text] [Related]
8. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus: a new approach to an old disease.
Weller PM; Greissman AM
Nurs Spectr (N Engl Ed); 1998 Jan; 2(1):15. PubMed ID: 9546893
[No Abstract] [Full Text] [Related]
10. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
12. Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control.
Simon A; Khurana K; Wilkesmann A; Müller A; Engelhart S; Exner M; Schildgen O; Eis-Hübinger AM; Groothuis JR; Bode U
Int J Hyg Environ Health; 2006 Jul; 209(4):317-24. PubMed ID: 16697255
[TBL] [Abstract][Full Text] [Related]
13. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children.
Madhi SA; Kuwanda L; Cutland C; Klugman KP
J Clin Virol; 2006 Jul; 36(3):215-21. PubMed ID: 16678480
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
DeVincenzo JP; Aitken J; Harrison L
J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
[TBL] [Abstract][Full Text] [Related]
15. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
Cox RA; Rao P; Brandon-Cox C
J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
[TBL] [Abstract][Full Text] [Related]
16. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab for respiratory syncytial virus prophylaxis.
Sandritter T
J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
[TBL] [Abstract][Full Text] [Related]
18. RSV and the infant.
Glidden C
Home Care Provid; 2000 Feb; 5(1):10-1. PubMed ID: 10835139
[No Abstract] [Full Text] [Related]
19. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
20. Prevention of respiratory syncytial virus infection in high risk infants.
Prince AM; Jacobs RF
J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
